Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Xuran Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea. Hauptthemen laut MEDLINE: Triazines, Radiopharmaceuticals, Membrane Proteins, Gelatinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Dimeric fibroblast activation protein inhibitor (FAPI) radioligands are promising candidates for theranostic applications because of their enhanced tumor uptake and prolonged retention compared to monomeric radioligands. Several linker strategies have been investigated to connect two FAPI motifs and a radiometal chelator in a dimer design. In this study, we report the development of a novel dimeric FAPI radioligand, [68Ga]Ga-1, which utilizes a triazine core as a trifunctional linker. The ligand [natGa/68Ga]Ga-1 was synthesized by chelating gallium or gallium-68 to 2-(DOTAGA-NH-ethyl-NH)-4,6-bis(Gly-FAPI)-1,3,5-triazine (1). [natGa]Ga-1, a nonradioactive ligand, exhibited FAP-binding affinity comparable to that of FAPI-04 (IC50 = 2.42 nM vs 1.57 nM). [68Ga]Ga-1 was synthesized in high decay-corrected radiochemical yields (91.7-94.7%) with high molar activities (40.8-50.0 GBq/μmol) and showed good stability in phosphate-buffered saline and fetal bovine serum. In vitro studies confirmed FAP-specific cellular uptake of [68Ga]Ga-1. Positron emission tomography (PET) imaging and ex vivo biodistribution of [68Ga]Ga-1 in U87MG tumor-bearing mice demonstrated high tumor uptake and retention, which were significantly blocked by FAPI-04, confirming FAP specificity. Notably, [68Ga]Ga-1 demonstrated superior and more sustained tumor uptake than monomeric [68Ga]Ga-FAPI-04, indicating improved pharmacokinetics. Altogether, the triazine linker is well suited for constructing dimeric FAPI radioligands, and [68Ga]Ga-1 holds potential as a FAP-targeted radioligand for theranostic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
ORCID-Profile: Yearn Seong Choe
Förderung
- National Research Foundation of Korea
Zitieren
APA
Zhang, X., Kang, C. M., Choi, J. Y., & Choe, Y. S. (2025). Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00979
Vancouver
Zhang X, Kang CM, Choi JY, Choe YS. Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00979
BibTeX
@article{Zhang2025,
author = {Zhang, Xuran and Kang, Choong Mo and Choi, Joon Young and Choe, Yearn Seong},
title = {Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00979}
}
EUVIMED